Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2Phase 3 Interventional Results available

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

ClinicalTrials.gov ID: NCT02186301

Public ClinicalTrials.gov record NCT02186301. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not previously received any treatment for advanced/metastatic EGFR mutated NSCLC. This study is a 'Randomized' Study. This means that upon entering the study, patients will be randomly assigned to be dosed with either rociletinib twice a day or erlotinib once a day. Patients will continue to take either rociletinib or erlotinib until it is no longer beneficial.

Study identification

NCT ID
NCT02186301
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Clovis Oncology, Inc.
Industry
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2014
Primary completion
Jun 27, 2017
Completion
Jun 27, 2017
Last update posted
May 6, 2019

2014 – 2017

United States locations

U.S. sites
54
U.S. states
21
U.S. cities
50
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35294
East Valley Hematology and Oncology Medical Group, Inc. Burbank California 91505
City of Hope Duarte California 91010
Compassionate Cancer Care Medical Group, Inc. Fountain Valley California 92708
St. Joseph Heritage Healthcare Fullerton California 92835-3825
UC San Diego Moores Cancer Center La Jolla California 92093-0698
University of Southern California, Norris Comprehensive Cancer Center Los Angeles California 90089
Sutter Medical Group Sacramento California 95816
University of California San Francisco San Francisco California 94115
Sansum Clinic Santa Barbara California 93105
Central Coast Medical Oncology Corporation Santa Maria California 93454
UCLA Medical Center Santa Monica California 90404
The Oncology Institute of Hope and Innovation Whittier California 90603
University of Colorado Cancer Center Aurora Colorado 80045
Georgetown University Medical Center Washington D.C. District of Columbia 20007
Cancer Specialists of North Florida Fleming Island Florida 32003
Florida Cancer Specialists and Research Institute Fort Myers Florida 33916
Advanced Medical Specialties Miami Florida 33176
Florida Hospital Cancer Institute Orlando Florida 32804
Florida Cancer Specialists St. Petersburg Florida 33705
Cleveland Clinic Florida Weston Florida 33331
Northwestern University Chicago Illinois 60611
University of Illinois Cancer Center Chicago Illinois 60612
Illinois Cancer Specialists Niles Illinois 60714
Harry and Jeanette Weinberg Cancer Institute at Franklin Square Baltimore Maryland 21237
Walter Reed Army Institute of Research Bethesda Maryland 20889
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201
Oncology Hematology West PC Omaha Nebraska 68130
Comprehensive Cancer Centers of Nevada Henderson Nevada 89014
Regional Cancer Care Associates, LLC East Brunswick New Jersey 08816
Regional Cancer Care Associates Morristown New Jersey 07962
Roswell Park Cancer Institute Buffalo New York 14263
Montefiore Medical Center The Bronx New York 10461
Duke University Medical Center Durham North Carolina 27710
University of Cincinnati Medical Center Cincinnati Ohio 45267
University Hospitals Case Medical Center Cleveland Ohio 44106
Cleveland Clinic Cleveland Ohio 44195
Oregon Health and Science University Portland Oregon 97239
Thomas Jefferson University Hospital Philadelphia Pennsylvania 19107
Hollings Cancer Center Charleston South Carolina 29425
Tennessee Oncology, PLLC Chattanooga Tennessee 37404
Tennessee Oncology, PLLC Nashville Tennessee 37203
USC/Norris Comprehensive Cancer Center Nashville Tennessee 37212-3505
Texas Oncology, PA Austin Texas 78745
Texas Oncology-Beaumont Beaumont Texas 77702
Texas Oncology, P.A. Bedford Texas 76022
University of Texas Southwestern Medical Center Dallas Texas 75390-8852
Houston Methodist Cancer Center Houston Texas 77030
The University of Texas - MD Anderson Cancer Center Houston Texas 77030
Texas Oncology-Plano East Plano Texas 75075-7753
Virginia Cancer Specialists, PC Fairfax Virginia 22031
University of Washington Seattle Washington 98109
Northwest Cancer Specialists, P.C. Vancouver Washington 98684
Yakima Valley Memorial Hospital, North Star Lodge Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02186301, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 6, 2019 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02186301 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →